Related Experiment Video

Updated: Jul 17, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Cytotoxicity of different selective serotonin reuptake inhibitors (SSRIs) against cancer cells

M Rosetti1, M Frasnelli, A Tesei

  • 1Istituto Oncologico Romagnolo (IOR), Italy.

Journal of Experimental Therapeutics & Oncology
|January 19, 2007
PubMed

Insights

Paroxetine, a selective serotonin reuptake inhibitor (SSRI), shows anticancer potential by inhibiting cancer cell growth. Other SSRIs like venlafaxine did not exhibit similar cytotoxic effects on tumor cells.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Altered cell membrane ion transporter expression is a hallmark of cancer.
  • Serotonin reuptake inhibitors (SSRIs) are being investigated for their anticancer properties.

Purpose of the Study:

  • To compare the anticancer efficacy of two SSRIs: paroxetine (serotonin-specific) and venlafaxine (serotonin, norepinephrine, and dopamine transporter inhibitor).
  • To evaluate the cytotoxic activity of these SSRIs against various murine and human cancer cell lines.

Main Methods:

  • Treatment of murine and human cancer cell lines with paroxetine and venlafaxine.
  • Assessment of cell viability and growth inhibition at varying concentrations.

Main Results:

  • Paroxetine demonstrated significant cytotoxic activity against both murine and human tumor cells in the micromolar range.
  • Venlafaxine did not show comparable cytotoxic effects on the tested cancer cell lines.
  • The findings suggest a non-neurotransmitter receptor-mediated mechanism for SSRI-induced cytotoxicity in cancer cells.

Conclusions:

  • Paroxetine exhibits anticancer potential, warranting further investigation for cancer therapy.
  • The specific inhibition profile of SSRIs influences their efficacy against cancer cells.
  • Understanding SSRI cytotoxicity mechanisms is crucial for defining their therapeutic applications in oncology.

More Related Videos

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Related Concept Videos

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...